Hansa Biopharma Ab Stock Return On Equity
| HNSBF Stock | USD 4.76 0.28 0.00% |
Hansa Biopharma AB fundamentals help investors to digest information that contributes to Hansa Biopharma's financial success or failures. It also enables traders to predict the movement of Hansa Pink Sheet. The fundamental analysis module provides a way to measure Hansa Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Hansa Biopharma pink sheet.
Hansa |
Hansa Biopharma AB Company Return On Equity Analysis
Hansa Biopharma's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Hansa Biopharma Return On Equity | -0.89 |
Most of Hansa Biopharma's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hansa Biopharma AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Hansa Biopharma AB has a Return On Equity of -0.8941. This is 96.27% lower than that of the Healthcare sector and 97.55% lower than that of the Biotechnology industry. The return on equity for all United States stocks is 188.42% higher than that of the company.
Hansa Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hansa Biopharma's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Hansa Biopharma could also be used in its relative valuation, which is a method of valuing Hansa Biopharma by comparing valuation metrics of similar companies.Hansa Biopharma is currently under evaluation in return on equity category among related companies.
Hansa Fundamentals
| Return On Equity | -0.89 | |||
| Return On Asset | -0.27 | |||
| Current Valuation | 189.89 M | |||
| Shares Outstanding | 52.44 M | |||
| Shares Owned By Insiders | 7.37 % | |||
| Shares Owned By Institutions | 41.33 % | |||
| Price To Earning | (46.57) X | |||
| Price To Book | 6.59 X | |||
| Price To Sales | 16.29 X | |||
| Revenue | 33.88 M | |||
| Gross Profit | 116.05 M | |||
| EBITDA | (538.83 M) | |||
| Net Income | (548.28 M) | |||
| Cash And Equivalents | 60.15 M | |||
| Cash Per Share | 1.58 X | |||
| Debt To Equity | 2.29 % | |||
| Current Ratio | 6.42 X | |||
| Book Value Per Share | 1.50 X | |||
| Cash Flow From Operations | (481.17 M) | |||
| Earnings Per Share | (0.65) X | |||
| Number Of Employees | 150 | |||
| Beta | 0.88 | |||
| Market Capitalization | 274.8 M | |||
| Total Asset | 1.01 B | |||
| Working Capital | 86 M | |||
| Current Asset | 105 M | |||
| Current Liabilities | 19 M | |||
| Net Asset | 1.01 B |
About Hansa Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hansa Biopharma AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hansa Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hansa Biopharma AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hansa Biopharma AB. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Hansa Biopharma AB information on this page should be used as a complementary analysis to other Hansa Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Complementary Tools for Hansa Pink Sheet analysis
When running Hansa Biopharma's price analysis, check to measure Hansa Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hansa Biopharma is operating at the current time. Most of Hansa Biopharma's value examination focuses on studying past and present price action to predict the probability of Hansa Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hansa Biopharma's price. Additionally, you may evaluate how the addition of Hansa Biopharma to your portfolios can decrease your overall portfolio volatility.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |